Figure 2.
Tau reduction prevents early mortality in hAPPJ9/Fyn mice and TASD41/Fyn mice. A, B, Kaplan–Meier survival plots in NTG, hAPPJ9, Fyn, and hAPPJ9/Fyn mice on the Tau+/+ (A) or Tau−/− (B) background. There was high mortality in hAPPJ9/Fyn/Tau+/+ mice (log-rank test vs other Tau+/+ groups, p < 0.0001) but not in hAPPJ9/Fyn/Tau−/− mice (log-rank test vs hAPPJ9/Fyn/Tau+/+, p < 0.0001). C, D, Kaplan–Meier survival plots in NTG, TASD41, Fyn, and TASD41/Fyn mice on the Tau+/+ (C) or Tau−/− (D) background. There was high mortality in TASD41/Fyn/Tau+/+ mice (log-rank test vs other Tau+/+ groups, p < 0.0001), whereas TASD41/Fyn/Tau−/− mice had longer survival (log-rank test vs TASD/Fyn/Tau+/+, p < 0.0001).